Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany

Jan B. Pietzsch, Benjamin P. Geisler, Annabelle R. Iken, Iris P.S. van Wijck, Suzanne Holewijn, Michel M.P.J. Reijnen

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Drug-coated balloons (DCBs) for femoropopliteal peripheral artery disease have been shown to be clinically superior and cost-effective compared to conventional percutaneous transluminal angioplasty (PTA). However, few studies enrolled patients with chronic limb-threatening ischemia (CLTI). Our objective was to study the cost-effectiveness of endovascular treatment with versus without DCB in CLTI patient populations in the Netherlands and Germany. Material and Methods: Target lesion revascularization (TLR) and major amputation rates were obtained from the CLTI subgroup of the IN.PACT Global study. Rates for “status quo” treatment involving PTA with primary or bailout stenting were derived from systematic literature search. Costs and cost-effectiveness were calculated using a decision-analytic Markov model considering, in the base case, a 2-year horizon, and strategy-specific quality-adjusted life year (QALY) gains calculated from survival and health state-specific utilities. A willingness-to-pay threshold of €50,000/QALY was assumed, and extensive sensitivity analyses were performed. Results: Model-projected 24-month probabilities of TLR were 26.2% and 32.8% for treatment with and without DCB, and probabilities for amputation were 2.8% and 11.9%, respectively. DCB added 0.017 QALYs while saving €1,030 in the Dutch setting and €513 in the German setting, respectively. DCB was found dominant or cost-effective across a wide range of assumptions. Conclusion: Urea excipient drug-coated balloon therapy for treating CLTI from femoropopliteal artery disease is associated with improved patient outcomes and expected overall cost savings to payers in the Dutch and German healthcare systems, rendering it a cost-effective and likely dominant treatment strategy.

Original languageEnglish
Pages (from-to)298-305
Number of pages8
JournalCardioVascular and Interventional Radiology
Volume45
Issue number3
Early online date2022
DOIs
Publication statusPublished - Mar 2022
Externally publishedYes

Keywords

  • Angioplasty [MeSH terms]
  • Cost–benefit analysis [MeSH terms]
  • Economic/cost-effectiveness
  • Germany [MeSH Terms]
  • Peripheral Arterial Disease [MeSH terms]
  • The Netherlands [MeSH Terms]

Fingerprint

Dive into the research topics of 'Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany'. Together they form a unique fingerprint.

Cite this